

Pharmacy and Therapeutics Committee

Formulary and Drug Management

October 3, 2022

Before We Get Started



Message
Lisa Silverman
for any *tech issues*



Use the chat box for
questions and to
introduce
yourself



Explore *resources*
we'll share in the
chat box



Donna Merrick

**Product
Enhancement
Principal**



Jenn Richards

**Product
Development
Principal**



Lisa Silverman

**Client Education
Specialist**

OPENING POLL

Does your health plan delegate P&T functions and/or formulary and drug management to a PBM?

Focus Areas

Pharmacy and
Therapeutics
Committee
(PBM-PT)

Formulary and
Drug
Management
(PBM-FDM)

Applicable Accreditation Programs



Health Plan v8.1
Marketplace Health Plan v8.1
Medicaid Health Plan v1.1

Health Plan v8.1

Marketplace Health Plan v8.1

Medicaid Health Plan v1.1

Pharmacy and Therapeutics Committee (PBM-PT)

PBM-PT 1: Committee Members

PBM-PT 2: Committee Meetings and Responsibilities

PBM-PT 1: Committee Members

Standard

The organization maintains a Pharmacy and Therapeutics Committee.

EPGs

PBM-PT 1-1:
Membership

PBM-PT 1-2: Conflict of
Interest

PBM-PT 1-3:
Membership Exclusions

PBM-PT 1-1: Membership

Various
Specialties

Majority
Practicing


Practicing
Elderly or
Disabled Care

Independent
of Conflict

Members of the Pharmacy and Therapeutics Committee include:

- a. Appropriate credentialed clinical specialists as stated in URAC's Credentialing Standard
- b. Various clinical specialties that represent the needs of the covered members
- c. A majority who are practicing physicians, practicing pharmacists or both
- d. At least one practicing physician and one practicing pharmacist who are experts regarding care of elderly or disabled individuals
- e. At least 50% of the practicing pharmacists and practicing physicians who are independent and free of conflict

PBM-PT 1-2: Conflict of Interest



Members of the Pharmacy and Therapeutics Committee must:

- a. Sign an initial conflict of interest statement and update it at least annually, revealing economic interests or relationships that could influence committee decisions

PBM-PT 1-3: Membership Exclusions

**NO
PRODUCT
SPONSORS**

The Pharmacy and Therapeutics Committee:

- a. Excludes product sponsor representatives from membership and from attending meetings

PBM-PT 2: Committee Meetings and Responsibilities

Standard

The Pharmacy and Therapeutics Committee meets regularly and performs their responsibilities.

EPGs

**PBM-PT 2-1:
Meetings**

**PBM-PT 2-2:
Responsibilities**


PBM-PT 2-1: Meetings



The Pharmacy and Therapeutics Committee:

- a. Holds meetings at least quarterly and documents in writing decisions and recommendations
- b. Has a process to convene ad hoc meetings if there is an emergent issue that needs to be reviewed

PBM-PT 2-2: Responsibilities



The Pharmacy and Therapeutics Committee:

- a. Evaluates and approves drugs and/or drug classes for the formulary based on scientific evidence, including drug safety and efficacy advantages
- b. Evaluates and approves utilization management activities based on scientific evidence
- c. Considers alternative drug products and therapies in terms of their effectiveness and impact on care quality, outcomes, and costs
- d. Timely considers new FDA-approved drug products or indications once released to the market
- e. Timely considers new evidence regarding a drug product or class

Poll

Does your health plan delegate to a PBM one, the other, or both?

- A. P&T functions
- B. Formulary and drug management
- C. Both A & B
- D. No delegation

Formulary and Drug Management (PBM-FDM)

PBM-FDM 1: Formulary Management

PBM-FDM 2: Formulary Exceptions and Coverage Exclusions


PBM-FDM 1: Formulary Management

Standard

The organization develops and reviews drug formularies to assure therapeutic appropriateness. **[M]**



PBM-FDM 1-1: Formulary Management



The organization's formulary development and review process includes:

- Integration of Pharmacy and Therapeutics Committee decisions
- Periodic review of drug and drug class therapeutic appropriateness (safety and efficacy)
- Addressing cost factors only after the safety, efficacy, side effect profile and therapeutic need have been established by the Pharmacy and Therapeutics Committee
- Review of formulary placement of the drugs within a therapeutic class at least annually

PBM-PT 2: Formulary Exceptions and Coverage Exclusions

Standard

The organization manages formulary exceptions and coverage exclusions.

EPGs


**PBM-FDM 2-1:
Formulary Exceptions**

**PBM-FDM 2-2:
Coverage Exclusions**

PBM-PT 2-1: Formulary Exceptions



Exception



Prior
Authorization

The organization:

- a. Allows members and prescribers to request a review for an exception to the formulary status of a prescription drug

PBM-PT 2-2: Coverage Exclusions



The organization has a process to:

a. Handle requests for drugs that are excluded from coverage under the benefit

Delegation to a PBM

Standard OPIN 1-2: Delegation Management applies.

OPIN 1-2: Delegation Management

Delegate to a URAC-accredited PBM?

Yes

Desktop Review

List of delegated functions

Delegation plan:
verify accreditation

No


Desktop Review

List of delegated functions

Delegation plan:
describe oversight

OPIN 1-2: Delegation Management

Delegate to a URAC-accredited PBM?



A large, white, 3D question mark stands on a light-colored wooden floor. The background is a plain, grey wall. The scene is lit from the left, casting a soft shadow of the question mark onto the wall.

Questions

Upcoming Events

Webinars

- Monthly AccrediNet Training
 - Wednesday, October 12
 - 2pm Eastern

Find more information at
clients.urac.org

